🧬
CRISPRO
.AI
HOME
BLOG
RECEIPTS
SAFETY
ORG
ENGINES
A+
CONFIRM CERTAINTY
NAVIGATE
HOME
BLOG
SAFETY
ORG · CRISPRO.ORG
RECEIPTS · TRIAL CASES
LATIFY
NCT05450692 · Ceralasertib (ATRi) + Durvalumab (PD-L1) · IO-refractory NSCLC
CEACAM5
NCT04154956 · Tusamitamab Ravtansine (CEACAM5 ADC) · NSCLC
ADAVOSERTIB
NCT03579316 · Adavosertib (WEE1i) + Gemcitabine · Recurrent solid tumors (ovarian focus)
CAPRI
NCT02264678 · Ceralasertib (ATRi) + Olaparib (PARPi) · Recurrent HGSOC
BERZOSERTIB
NCT02595892 · Berzosertib (ATRi) + Gemcitabine · Platinum-resistant ovarian carcinoma
ENGINES
TARGET-LOCK
AUC 0.822
MECHANISM ALIGNMENT
8D Vector
KILL CHAIN
AUROC 0.783
IO RISK-BENEFIT GATE
NCB Active
SYNTHETIC LETHALITY
d = −0.88
SAFETY & DOSING
100% CPIC
PREDICTION IS
CERTAINTY
.
ACTIVE GATE
_
FIVE PHASE III FAILURES. FIVE RECEIPTS. ZERO EXCUSES.
SEE THE RECEIPTS
TALK TO US
ORACLE
MATRIX
CEACAM5
LATIFY
ADAVOSERTIB
CAPRI
BERZOSERTIB
01/07